Latest / Pharmacy Podcast Network / Guess Who’s Back! Back Again! Topical Pain Medications Part 2: An Rx Encore! | PainPod
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:08Speaker 1: to the pharmacy profession.
- 0:10Speaker 2: Welcome to the Pharmacy podcast Network. This is the Pain Pod.
- 0:24Speaker 3: You want to see pain look at me?
- 0:33Speaker 4: Welcome to the Pain Pod, the podcast for all things
- 0:38Speaker 4: pain management, hosted by the pain Guy, doctor Mark grow.
- 0:47Speaker 3: We'll be collaborating with numerous pain management experts talking about
- 0:51Speaker 3: substance usage disorders, the latest treatment modalities, and the most
- 0:56Speaker 3: important important focusing on the pain of our page says
- 1:00Speaker 3: leading providers of pain care. And now here's our host.
- 1:07Speaker 3: A man wanted in all fifty states, a suburban city
- 1:11Speaker 3: like mountain man without the beard, from the hills of
- 1:16Speaker 3: West Virginia and certified in weapons.
- 1:20Speaker 2: Of mass destruction. Response. Yes, doctor Mark.
- 1:27Speaker 1: Slaby, All right, welcome back everyone to the Pain Pod.
- 1:34Speaker 1: So here today, Well we're going to do a little
- 1:37Speaker 1: follow up and encore if you will. So our most
- 1:40Speaker 1: previous episode was on topical pain medications. Well, we didn't
- 1:45Speaker 1: really devote a lot of time to the prescription side
- 1:48Speaker 1: of things. Talked about the big picture, of course, but
- 1:51Speaker 1: didn't do a warranted amount of effort there on the
- 1:55Speaker 1: prescription products, the FDA approved products. When it comes to
- 1:59Speaker 1: topical pain medications. So this is the encore. This is
- 2:03Speaker 1: topical pain medications Pert two here on the Pain Pod.
- 2:08Speaker 1: So big picture, of course, we got to remember that,
- 2:11Speaker 1: you know here in America, well we don't utilize a
- 2:15Speaker 1: lot of topical medications in general, but certainly topical pain
- 2:18Speaker 1: medications to the same degree that well everybody on the
- 2:21Speaker 1: rest of the planet does. Right. But hey, then again
- 2:24Speaker 1: comes to pain medicines, we're used to be in difference.
- 2:26Speaker 1: First up, there's the metric system and then well what
- 2:28Speaker 1: we do and you know, specifically, of course, there's also paracetamol.
- 2:33Speaker 1: The whole world calls it priorcetamol. We call it a
- 2:36Speaker 1: seedam infant and various other things. Right, so you know,
- 2:40Speaker 1: different strokes, different folks, were all different, and you know,
- 2:43Speaker 1: we got to keep that in mind overall, you know,
- 2:45Speaker 1: expanding our opening up our our minds, removing any blinders,
- 2:49Speaker 1: you know, for the utilization of topical pain medications overall. Now,
- 2:54Speaker 1: in the last episode, we touched on the you know,
- 2:56Speaker 1: the big picture, uh, you know, topical compared to transdermal.
- 2:59Speaker 1: The inherent differences of course for topical to the target
- 3:02Speaker 1: transderbal effects elsewhere as well, right, and then we broke
- 3:07Speaker 1: down things into the counter irritants, those that are warming
- 3:10Speaker 1: and cooling in their effects. For topical pain medications, then
- 3:14Speaker 1: of course we have the numbing options, the anti inflammation options,
- 3:19Speaker 1: and then a couple other options as well too, right,
- 3:22Speaker 1: But let's hone in on, you know, when thinking about
- 3:25Speaker 1: the bigger groups like counter irritants, numbing agents, inflammation agents,
- 3:29Speaker 1: and then the rest of the crew, let's jump back
- 3:31Speaker 1: to those counter irritants that idea right there for our
- 3:34Speaker 1: conversation today, you know, involving the prescription side. So let's
- 3:38Speaker 1: take that journey right.
- 3:40Speaker 2: So again with.
- 3:40Speaker 1: Counter irritants, we're thinking causing hot causing cold. There is
- 3:44Speaker 1: a difference, of course, you know, heat, you know resulting
- 3:47Speaker 1: in vasodilation cold, vasal constriction. There's differences there, of course.
- 3:53Speaker 1: But you know what we want to hone in here
- 3:55Speaker 1: on is probably within the warming agents are caps asoids
- 4:01Speaker 1: or a little bit easier to say capsasin right ery,
- 4:05Speaker 1: if you remember how it works, it's a trip V
- 4:07Speaker 1: one agonist. We we you know, we went over that
- 4:09Speaker 1: in the previous episode. But in a nutshell, a TRPV
- 4:14Speaker 1: one agonist was found to be you know, the mechanism
- 4:17Speaker 1: how the thing's working in the background for you know,
- 4:21Speaker 1: within the human body. In fact, of course, just the
- 4:24Speaker 1: reminder that there was actually a twenty twenty one Nobel
- 4:27Speaker 1: Prize in Physiology and Medicine for discovering the two scientists that.
- 4:32Speaker 2: Discover that, you know, the way that our bodies.
- 4:35Speaker 1: Sense and perceive and process is probably the best word
- 4:39Speaker 1: hot and cold would be TRPV one or hot trip
- 4:43Speaker 1: V one hot, and then TRP M eight or trip
- 4:47Speaker 1: them eight for processing cold sensations. Right, Well, if it's
- 4:52Speaker 1: good enough for Nobel Prize, good enough for discussing on
- 4:55Speaker 1: the pain pod even twice, right, But trip V one
- 4:58Speaker 1: we're going to hold it on that. That's the hot
- 5:00Speaker 1: side right coming in hot boom transient receptor potential CADI
- 5:04Speaker 1: on channels subfamily V right number one, where we could
- 5:08Speaker 1: say trip V one right, So overall functions detecting and
- 5:12Speaker 1: even regulating heat as well, works with an inflammation along
- 5:16Speaker 1: the way as well too. Now we previously talked about
- 5:19Speaker 1: the OTC options for cap sasin you know, the poster
- 5:22Speaker 1: children for the little fingercuts to not get that stuff
- 5:24Speaker 1: in your eye. Right, But on the prescription side there
- 5:27Speaker 1: we've got you know, we want to dive into that
- 5:30Speaker 1: realm overall, so there's a much higher octane patch kind
- 5:36Speaker 1: of struggle on calling it a patch. Most people will
- 5:39Speaker 1: say a patch, right, but in all reality, it's like
- 5:42Speaker 1: a delivery system, and that would be the eight percent
- 5:46Speaker 1: cap SASIN delivery system. Right, A lot of people say patch,
- 5:53Speaker 1: you know, brand name wise. We're talking to Tenza that's
- 5:56Speaker 1: got two different FDA approvals, one for poster petic neuralogia
- 6:00Speaker 1: so PHN, and they're one for diabetic periphie neuropathy or DPN.
- 6:05Speaker 1: Now there's differences abound when it comes to the two
- 6:08Speaker 1: different approvals for that particular formulation. The overall idea is
- 6:14Speaker 1: that the application is done you know, in a office
- 6:18Speaker 1: right in say like a clinic or amcare or you
- 6:20Speaker 1: know whatever we're thinking there. This isn't hey pick the
- 6:23Speaker 1: prescription up at the pharmacy and go home. This is
- 6:25Speaker 1: involving a healthcare professional right. In fact, the you know,
- 6:30Speaker 1: for post or pedic neurologia, you're you're looking at a
- 6:32Speaker 1: one hour application. Now that's not one hour of work,
- 6:35Speaker 1: that's one hour of a patient, you know, laying back
- 6:37Speaker 1: and having that delivery device, you know, kind of like
- 6:41Speaker 1: a tape perhaps if you will, but a lot of
- 6:44Speaker 1: people refer to as a patch, you know, overall being
- 6:47Speaker 1: applied for sixty minutes. Okay, a little bit of prep
- 6:50Speaker 1: before that as well too, and afterwards, usually do that
- 6:52Speaker 1: every three months. Now for the other indication for diabetic
- 6:55Speaker 1: proofer neuropi, there you're looking at half an hour, so
- 6:58Speaker 1: it cuts the time and half and again you're talking
- 7:01Speaker 1: feet typically, you know, for DPN and the larger area
- 7:05Speaker 1: for p H and overall, so you know, you got
- 7:07Speaker 1: to think about the patient experience throughout that, you know,
- 7:09Speaker 1: just kind of jilling, un kind of intended sitting back
- 7:13Speaker 1: and having that applied for either half an hour an hour,
- 7:16Speaker 1: depending on the condition that the patient has along the way.
- 7:19Speaker 1: A couple of unique things you know, in general. Sometimes
- 7:23Speaker 1: you know, in the studies anyway, i Alwa was found
- 7:25Speaker 1: that some people won't respond to the treatment initially. In fact,
- 7:28Speaker 1: it might take a good number of times of applications
- 7:31Speaker 1: to get the response, you know.
- 7:33Speaker 2: But in the end, hey, it's all about you.
- 7:35Speaker 1: Know, improving function and reducing pain overall, you know, the
- 7:38Speaker 1: biole and get one in the big picture. So some
- 7:41Speaker 1: big picture things to keep in mind, overall. But there
- 7:44Speaker 1: of course, you know, we're you know, we're talking about
- 7:47Speaker 1: diabetic profer neuropoity, a couple of things I want to
- 7:49Speaker 1: mention there. So yeah, symptoms of course, typically it's the
- 7:51Speaker 1: feet and legs, you know, for first offenders or first
- 7:55Speaker 1: noticing you're going to have that typical neuropathy descriptions with
- 7:58Speaker 1: a patient. You know, burning, stabbing, tingling, lightning, numbness, all that, right,
- 8:05Speaker 1: you know how you could actually feel that? So check
- 8:07Speaker 1: this out. I have to admit I actually endeavored into this.
- 8:10Speaker 1: If if somebody has never experienced neuropathy and would like
- 8:14Speaker 1: to know what are patients in pain with neuropathy or feeling,
- 8:18Speaker 1: check with your healthcare provider before doing anything like this, or.
- 8:21Speaker 2: Just take my word for it.
- 8:22Speaker 1: But if you go into a hot tub and then
- 8:24Speaker 1: immediately go into one of those super cold tubs, odds
- 8:28Speaker 1: are you gonna feel neuropathy pretty instantaneously and pretty profoundly.
- 8:32Speaker 2: Been there, done that, There wasn't a T shirt. Please
- 8:35Speaker 2: just take my word for it.
- 8:36Speaker 1: That is a way for the common person to kind
- 8:40Speaker 1: of be there and understand what a patient's going through. Okay,
- 8:44Speaker 1: all right, So generally with DPN, you know, symptoms are
- 8:47Speaker 1: gonna be worse at night. There's gonna be a little
- 8:50Speaker 1: bit less feeling to changes in temperature. I'm not necessarily
- 8:54Speaker 1: the weather report, but just you know, in the inherent area,
- 8:57Speaker 1: and certainly touch is going to be a thing, you know,
- 8:59Speaker 1: more sensitive the overall.
- 9:01Speaker 2: As far as diagnosis.
- 9:02Speaker 1: For DPN, first thing you want to do is rule
- 9:05Speaker 1: out other things, like, hey, is there you know any
- 9:07Speaker 1: vitamin B twelve deficiencies or concerns.
- 9:10Speaker 2: That's a big one, folks.
- 9:11Speaker 1: You think about it like, I mean, the name, the
- 9:13Speaker 1: name is diabetic peripheral neuropoty. Right, So patient with diabetes,
- 9:17Speaker 1: what's one of the most common medications I know these
- 9:20Speaker 1: days we're thinking of, you know, maybe an injectible or two,
- 9:23Speaker 1: but regardless of bigger what country you're in. But met foreman,
- 9:28Speaker 1: right comes in mind. What's one of those side effects
- 9:31Speaker 1: we got to watch for. Well, you know, it affects
- 9:33Speaker 1: the absorption for vitamin B twelve, so there could be
- 9:36Speaker 1: some deficiencies. So it's like, hey, you know, chicken or
- 9:39Speaker 1: egg here for where dPN's coming from. You know, just
- 9:43Speaker 1: ruling out other causes. That's one of many of course too.
- 9:46Speaker 1: So now nerve function tests are actually the lay of
- 9:49Speaker 1: the land of things like film and tests EMG or
- 9:52Speaker 1: nerve conduction velocity tests just to name a hot three there,
- 9:56Speaker 1: but nerve function tests, that's really the lay of the
- 9:58Speaker 1: land overall, once ruling out other ideas. Now, in twenty
- 10:03Speaker 1: twenty two, there were new treatment guidelines that were proposed
- 10:08Speaker 1: basically from A A N. I have all of these
- 10:11Speaker 1: certainly within our show notes and all that, but like
- 10:13Speaker 1: every guideline pertained to pain management, you could readily accept
- 10:16Speaker 1: access these here on pain guy dot us my website.
- 10:20Speaker 1: Of course, if you go to the resources tab on
- 10:23Speaker 1: pain guy dot us, you can access pretty much any
- 10:27Speaker 1: pain management guideline you're going to want to look for.
- 10:29Speaker 1: And if I'm missing something, folks, let me know. The
- 10:31Speaker 1: little chat bottle come up message me comes to me,
- 10:35Speaker 1: call it a day, right, I digress. So for DPN,
- 10:39Speaker 1: there's multiple recommendations, of course, within those guidelines. The fifth
- 10:43Speaker 1: one actually break it up to two separate ports, but
- 10:46Speaker 1: basically they're emphasizing that, hey, clinicians should assess for patient
- 10:50Speaker 1: preferences for formulations, one of them being topical, and if
- 10:55Speaker 1: the patient prefers something likly topical or whatever else, consider
- 10:59Speaker 1: that route, right. They actually say, hey, if you're considering
- 11:02Speaker 1: topical for DPN, then consider cap sation amongst a couple
- 11:06Speaker 1: other things, right. So that's that's where we're in the
- 11:09Speaker 1: realm here overall. Now, if you're diving further into this
- 11:14Speaker 1: particular product for DPN or PHN, you know the cap
- 11:18Speaker 1: sason eight percent, there's you know, the studies are out there.
- 11:21Speaker 1: You could certainly look them up. We can include them
- 11:23Speaker 1: as well too for show notes. But the general idea
- 11:26Speaker 1: is that, hey, there's FDA approval, so there is proven
- 11:29Speaker 1: safety and neppica is he right, pretty obvious there, You
- 11:32Speaker 1: know what. One of the bigger picture questions though, is
- 11:35Speaker 1: what that application?
- 11:36Speaker 3: Right.
- 11:37Speaker 1: So typically you know you're you're having what you could
- 11:41Speaker 1: call patches, but it's really like large films, you know,
- 11:45Speaker 1: a picture like old school not looking at digital X rays,
- 11:47Speaker 1: but you know, looking at the actual films, right, But
- 11:50Speaker 1: you could be hutting those in certain ways to be
- 11:53Speaker 1: able to wrap them around the foot. You know you're
- 11:55Speaker 1: going to have a clinician doing that. The actual application
- 11:58Speaker 1: where you know often times first have a local anesthetic apply,
- 12:02Speaker 1: then you know, cut to the size of what's needed. Certainly,
- 12:05Speaker 1: utilizing nitrial gloves of note not latex, and then you know,
- 12:10Speaker 1: have that application on there for a half an hour
- 12:12Speaker 1: for DPN for patients. Afterwards, taking that film or patch
- 12:17Speaker 1: if you want to call it that off, you're rolling
- 12:19Speaker 1: it inward that you know, basically makes it so that
- 12:21Speaker 1: you're not getting any of the ingredient anywhere. And then
- 12:25Speaker 1: there's a cleansing gel and you know, wipe it up
- 12:27Speaker 1: and we call it a day. Along the way there
- 12:28Speaker 1: still got a telepatient. You know, hey, watch out for
- 12:31Speaker 1: any like you know, hot showers or you know, hot
- 12:33Speaker 1: liquids in general, any irritation like that sun you know
- 12:37Speaker 1: when sunburn. Of course, exercise things like that, you know,
- 12:40Speaker 1: just for the next few days overall. I did mention
- 12:43Speaker 1: that products actually also approved for post re pedican nouralasia.
- 12:47Speaker 1: That's that's a tough one, right, Yeah, you think about
- 12:50Speaker 1: those times of wind. Do you want to explain pain, well,
- 12:52Speaker 1: post for pedic nolage as far as neuropiity goes foo
- 12:55Speaker 1: doggie right, burning, shaking, electric shock, like pain, got that
- 13:00Speaker 1: sensitivity to touch, you got itching, numbness, you name it.
- 13:04Speaker 1: Like the perfect opportunity to cover things like aldinia hyper
- 13:09Speaker 1: algesia dysthesia. It's usually pain that's at least three months
- 13:14Speaker 1: after a shingles rash heels, hence post herpetic neuralgia. Right,
- 13:19Speaker 1: the pains typically where the shingles occurred. And you know,
- 13:22Speaker 1: the remarkable part would be, hey, there's that type of
- 13:24Speaker 1: pain and you had shingles about three months ago.
- 13:28Speaker 2: Right now, as far as treatment, we have our options.
- 13:31Speaker 1: You know, again these types of guidelines available on pain
- 13:35Speaker 1: Guy dot Us as well, but you got you know, oral,
- 13:38Speaker 1: you're typically looking at things like TCA's or you have
- 13:40Speaker 1: a pennoid's injectables or gook oft corticoid option with methaprotnislone.
- 13:46Speaker 1: Topical wise though, hey, that's we're here for right topical
- 13:49Speaker 1: pain medications. So there, we're typically looking at things like
- 13:52Speaker 1: ldacane patches. We talked about the numbing agents previously, you know,
- 13:56Speaker 1: topical capsation as we mentioned aspirin cream, TCA cream like
- 14:00Speaker 1: doccipin as well too. So now one thing when mentioning
- 14:04Speaker 1: PHN poster petican aroundia and ounce of prevention is worth
- 14:07Speaker 1: well a lot of treatment, right So there, we're always
- 14:10Speaker 1: wanting to talk with patients in the public everybody about
- 14:14Speaker 1: you know, the recombinant and zoster vaccine or RZV shingricks,
- 14:18Speaker 1: you know, for preventing it in the first place, right,
- 14:22Speaker 1: all right, so that was a that was a decent
- 14:24Speaker 1: amount there on capsa syn topically in a prescription form.
- 14:28Speaker 1: We also casually about thirty seconds ago, started talking about
- 14:31Speaker 1: well what about lightocane. So let's bring that up again
- 14:34Speaker 1: because we have some options when it comes to the
- 14:36Speaker 1: prescription side again lydakane. You know, as a reminder, it's
- 14:40Speaker 1: working on those old sodium potassium pumps that we all
- 14:43Speaker 1: were subjected to probably week two of freshman year in biology,
- 14:48Speaker 1: right we all got to learn our sodium potassium pumps.
- 14:51Speaker 2: Why, well, probably.
- 14:52Speaker 1: For this podcast right now, everybody has a seat at
- 14:55Speaker 1: the table. Anyways, when it comes to transdermal lytacane, I
- 15:00Speaker 1: just want to mention it. It's not topical. We're here
- 15:02Speaker 1: for topicals, but you know it's worth a mention. There's
- 15:05Speaker 1: a couple of nuances here as well, too, Like, for instance,
- 15:08Speaker 1: you know, for our transdrmalodi kane options prescription side, there's
- 15:13Speaker 1: dermalid they're one of the recommendations for patients is to
- 15:16Speaker 1: avoid water there's lighterderm available as generics of course also
- 15:21Speaker 1: want to avoid water. There's ztlido relatively higher cost, but
- 15:27Speaker 1: that's going to depend on formula coverage all that great stuff.
- 15:30Speaker 1: But you avoid the need to avoid water, which is
- 15:34Speaker 1: kind of cool right upun intended Again, that's one of
- 15:38Speaker 1: the you know, just making things more easier to incorporate
- 15:42Speaker 1: into people's lives. But again we have our balance of
- 15:44Speaker 1: what's available as far as products and all that, all
- 15:47Speaker 1: of them, though it's twelve hours on twelve hours off,
- 15:50Speaker 1: incredibly important to go over a patient, right that that's
- 15:54Speaker 1: really important in the big picture.
- 15:56Speaker 2: All right, So let's see talked about.
- 15:59Speaker 1: You know, the the not necessarily need to avoid liquid
- 16:02Speaker 1: slash water, you know, the whole exercise concerns, showering, bathing
- 16:06Speaker 1: concerns with ztlido for that transfermal ldakane that it uses
- 16:11Speaker 1: a different technology in the formulation, right basically, and it's
- 16:17Speaker 1: known as the one point eight percent that's relatively equivalent
- 16:21Speaker 1: based on multiple references to about five percent of the
- 16:24Speaker 1: lighto kane patch because both are going to aim to
- 16:27Speaker 1: deliver fifteen miligrams of lighter caine just to be specific.
- 16:30Speaker 1: But it's all in the formulations, right, But again the
- 16:33Speaker 1: big picture is, you know there's no head to head
- 16:35Speaker 1: studies for all these things, but you know the whole
- 16:38Speaker 1: exercise bathing, all that kind of stuff, right, all right,
- 16:41Speaker 1: so that's our numbing agents. Let's jump ship and go
- 16:45Speaker 1: over to the inflammation topical typically prescription in medication options, right,
- 16:53Speaker 1: it's all about diclofinac then. Right, So on the prescription side,
- 16:57Speaker 1: we have topical diclof patches, multiple topical uh dicloth X
- 17:06Speaker 1: solution we got one there basically, and then topical dicloth
- 17:09Speaker 1: nec gel which is also available over the counter. Now right,
- 17:12Speaker 1: we touched on that one in the previous episode if
- 17:14Speaker 1: you want to tag them up together here. But let's
- 17:17Speaker 1: you know, jump a little bit into these prescription versions
- 17:22Speaker 1: of topical diclothfinc for inflammation. So first up with the patches.
- 17:28Speaker 1: We of course one of the first ones here is
- 17:30Speaker 1: basically flector and that is you know, certainly a proof
- 17:34Speaker 1: of acute care. The dosing is twice daily. That's pretty
- 17:38Speaker 1: much the important thing there to remember with you know,
- 17:41Speaker 1: the the that particular formulation, the generic flector patch, dicloth
- 17:47Speaker 1: NEC that is being twice daily because then there's also
- 17:52Speaker 1: ironically from the same company I believe, at least originally
- 17:57Speaker 1: is the like heart patch which is once daily, right,
- 18:00Speaker 1: also just to prove for acute care overall.
- 18:03Speaker 2: But the the overall idea.
- 18:04Speaker 1: There is that you know, again going closer to that
- 18:08Speaker 1: making it easier to incorporate into one's life. Some people
- 18:13Speaker 1: might prefer to have more hands on approach, you know,
- 18:15Speaker 1: with more often throughout the day. Others are leading busy lives.
- 18:19Speaker 1: Once a day can be a big difference compared to
- 18:20Speaker 1: twice today, right, all right, now, I also mentioned the
- 18:24Speaker 1: topical diclofen x solution or pen set available to nearic
- 18:28Speaker 1: of course as well. That's your your two percent solution.
- 18:33Speaker 1: You know, the actual not necessarily formulation, but the delivery
- 18:37Speaker 1: container has changed throughout the years and decades really, but
- 18:41Speaker 1: now it's a three point eight ounce bottle. Got to
- 18:43Speaker 1: watch that for TSA and traveling, right because it's over
- 18:45Speaker 1: three ounces. Yeah, in the pain pile, we get nitty
- 18:48Speaker 1: and gritty with what we can help patients with, right,
- 18:50Speaker 1: got to think about these things, right. Of course, that
- 18:54Speaker 1: formulation has that d MSO penetration enhancer in its die
- 18:59Speaker 1: methyl sulfar side. And yes, if you listen to the
- 19:02Speaker 1: previous episode of the Paint Pod, you will certainly remember
- 19:05Speaker 1: that that has a low likelihood but a possibility of
- 19:08Speaker 1: a side effect of garlic breath, even though it's applied topically, right,
- 19:12Speaker 1: good golly, it's one percent of patients. But still it's
- 19:16Speaker 1: because of that DMSO and how it's basically I guess
- 19:19Speaker 1: we'll say metabolized or change within the body to end
- 19:22Speaker 1: up with some water and dimethyl sulfide, which you guessed
- 19:25Speaker 1: it smells like darlic, right, So yeah, it's not just
- 19:28Speaker 1: an Italian thing, has nothing to do with my family
- 19:30Speaker 1: vineyard over in the back of the boot in Italy.
- 19:32Speaker 1: It's actually a topical inset right all right. Now, on
- 19:36Speaker 1: the previous episode we talked about the otcvill taranjel. Same
- 19:41Speaker 1: idea here for the prescription version. Of course, it's been
- 19:44Speaker 1: approved prescription wise for almost twenty years. But you know
- 19:50Speaker 1: there are some little tags with the pearls if you
- 19:52Speaker 1: will that. You know it's two to four grams, four
- 19:55Speaker 1: times daily for a patient and it may take a
- 19:58Speaker 1: week to see efficacy, so you know there's nuances there
- 20:01Speaker 1: along the way.
- 20:02Speaker 2: As well too.
- 20:03Speaker 1: It's really intended for osty orthritis, joint pain, thinking hands, knees,
- 20:07Speaker 1: and feet, not for other stuff like strains, sprains, bruises,
- 20:11Speaker 1: sports injuries. You name it, right, all right, A big picture,
- 20:16Speaker 1: you know, as far as dosing. If you're talking up top,
- 20:19Speaker 1: like you know, hands, like I mentioned there previously, you're
- 20:24Speaker 1: thinking two grams, but down below for knees and feet,
- 20:27Speaker 1: you're thinking four grams. And there's usually a dosing card
- 20:30Speaker 1: that will help a patient visually see how much to
- 20:33Speaker 1: squeeze out of the tube, right, typically lessens up in
- 20:36Speaker 1: But what is intended when you're talking about topical agents overall?
- 20:42Speaker 1: All right, So let's you know, one other one I
- 20:44Speaker 1: mentioned here too was topical docs a pin. It's the
- 20:47Speaker 1: Zono long cream. It's a prescription of course, so they're
- 20:50Speaker 1: you know, localized, tricyclic and depressed and TCA. It's approved
- 20:54Speaker 1: you know, four times a day for itching. But hey,
- 20:57Speaker 1: what about neuropathic pain as well too, right, So that's
- 21:00Speaker 1: that's something we want to put in there. We saw
- 21:01Speaker 1: that in the guideline when we were talking earlier. You know, overall,
- 21:06Speaker 1: you know, again with those guidelines readily available on pain
- 21:09Speaker 1: Guy dot Us, But that came up when we were
- 21:11Speaker 1: talking about post repedic neurology as far as the guideline there,
- 21:14Speaker 1: you know, just recommendations in general too. So that's you know,
- 21:18Speaker 1: that's the core, the really the key core ingredients, formulations, products.
- 21:24Speaker 1: We're talking prescription topical pain medications as we break them
- 21:28Speaker 1: down to counter irritants, the war and the hot and
- 21:30Speaker 1: the gold numbing inflammation. And then Doc's been kind of
- 21:34Speaker 1: hanging out in his own island. But wait, there's there's
- 21:37Speaker 1: so much more too, right, I mean when you think
- 21:40Speaker 1: about it like, there's you know, of course there's compounded medications.
- 21:44Speaker 1: You know, pharmacies that are compounding topical options. Common ingredients
- 21:48Speaker 1: there run through a laundry list, things like keta meant
- 21:51Speaker 1: prof and backli fin, benzicicine cyclo benz are bringing quantity
- 21:55Speaker 1: and gabapent and take any and every combination of those. Right,
- 21:59Speaker 1: there's spit things like gabapentin, chlanitine in pleuronic calecthin organo jail.
- 22:04Speaker 1: If I said that correctly, pillow p l O, let's
- 22:06Speaker 1: go with that. There's the triple anesthetic benzicane leticane tetracine
- 22:11Speaker 1: b l T no bacon included. Right, what other things
- 22:15Speaker 1: have we seen? Ketamine, ketoprofen, gabapentin. There's back plow so
- 22:21Speaker 1: you got that, you know, pl o again, but with
- 22:24Speaker 1: backlofini and a tripleing ketamine. I've seen app no typically
- 22:28Speaker 1: with ivy profen. So that's the l purpose nip ointment
- 22:32Speaker 1: beta methasone valerate viapyisone miconazole, and then that plus ivu
- 22:37Speaker 1: profil along the way. There's many, many more of course,
- 22:40Speaker 1: as far as the compounds, then we also have less
- 22:43Speaker 1: known prescription on topical agents that that are you know,
- 22:47Speaker 1: FDA approved readily available where these things don't actually even
- 22:51Speaker 1: have to be compounded overall, So you know, we certainly
- 22:55Speaker 1: want to keep that in mind as well too. There's
- 22:58Speaker 1: things like ketoprof and topical gabapent and topical cream. They're
- 23:02Speaker 1: they're already made, they're readily available, so you can certainly
- 23:05Speaker 1: check that out, you know as well in the big
- 23:08Speaker 1: picture too. All Right, so that was a lot a
- 23:11Speaker 1: lot of the you know, the core prescription products that
- 23:13Speaker 1: compounded and the lesser known prescription products. But wait, there's more.
- 23:19Speaker 2: What more could there be? You ask, well, you know,
- 23:21Speaker 2: we didn't cover a.
- 23:22Speaker 1: Little bit more on that CBD topical formulation, right, yeah,
- 23:27Speaker 1: encore of an encore. So let's cover topical CBD on
- 23:31Speaker 1: the tip of everyone's tongue and a question that's quite
- 23:34Speaker 1: frankly observed to be very frequently asked within our society.
- 23:37Speaker 2: Right, So let's go to the basics.
- 23:40Speaker 1: So, when we're talking cannabis, cannabinoids or even CBD specifically,
- 23:44Speaker 1: you got typically mechanisms of action, including CB one receptors
- 23:49Speaker 1: and CB two receptors. CB one think of the digit one,
- 23:53Speaker 1: it is all it is narrow, kind of like the CNS,
- 23:58Speaker 1: so those receptors are primarily in this CDs. The digit
- 24:01Speaker 1: the number two is a little bit wider, so I
- 24:03Speaker 1: remember that as being there all typically in the periphery
- 24:05Speaker 1: like immune system in GI track. Hopefully that helps, But
- 24:09Speaker 1: how do these things work?
- 24:10Speaker 2: Like CBD?
- 24:11Speaker 1: We're talking about CBD, right, So THHC is a partial
- 24:14Speaker 1: agonist at both CB one and CB two. CBD not
- 24:18Speaker 1: so much. CBD is an antagonist at CB one, the
- 24:22Speaker 1: opposite of THHC. It's also get this one, a negative
- 24:26Speaker 1: allosteric modulator at CB two, So kind of like the
- 24:29Speaker 1: opposite of THHC. But what the heck is a negative
- 24:32Speaker 1: allosteric modulator. Well, love covering that one. What I call
- 24:37Speaker 1: it is a backseat driver. Yep, you heard it here first,
- 24:40Speaker 1: a negative allosteric modulator. It talks about something interacting with
- 24:44Speaker 1: the receptor where it doesn't bind it the actual receptor.
- 24:46Speaker 1: It binds next door. But it will affect the outcome.
- 24:50Speaker 1: And that's why I call it a backseat driver. They're
- 24:52Speaker 1: not driving, they're back there. They'll have comments, they can
- 24:56Speaker 1: affect the outcome. Right, shout up to all of our
- 25:00Speaker 1: backseat drivers, right, good golly, all right? What else we
- 25:03Speaker 1: need to know about CBD? So as far as you know,
- 25:06Speaker 1: helping patients with selection, eventually we're talking topical here, but
- 25:09Speaker 1: you know there's full spectrum, broad spectrum in isolate. Full
- 25:13Speaker 1: spectrum simply includes all cannabinoids, including THHC. Broad spectrum all
- 25:17Speaker 1: the cannabinoids except THHC. As per labeling, and of course
- 25:22Speaker 1: the isolaate for a CB product is isolated, it's just
- 25:24Speaker 1: CBD as per the label. We do have our concerns
- 25:27Speaker 1: with labeling still these days. The most recent dynamic study
- 25:32Speaker 1: was from twenty twenty two that showed that a good
- 25:35Speaker 1: amount of the market is hitting the target for accuracy
- 25:39Speaker 1: and labeling for CBD content, but it's roughly about half
- 25:43Speaker 1: the market according to that study. So I imagine being
- 25:46Speaker 1: the company that does the due diligence and makes a
- 25:49Speaker 1: accurate labeled product, but everybody else in the market isn't
- 25:52Speaker 1: doing that, so you get a bad rep or vice
- 25:54Speaker 1: versa is concerning in the opposite direction. Right. The things
- 25:57Speaker 1: we got to keep in mind overall, turns out more
- 26:00Speaker 1: were patients, customers, consumers. Consumer Reports actually has a shopping
- 26:05Speaker 1: guide for CBD. I'll keep that in this show notes
- 26:08Speaker 1: for us too. But what are some things, you know,
- 26:11Speaker 1: one or two other things here just for our patients,
- 26:13Speaker 1: right and for ourselves to know. You always want to
- 26:16Speaker 1: be looking at the certificate of analysis. It's like the
- 26:18Speaker 1: rundown of the report of what's in this thing, right,
- 26:22Speaker 1: So they want to make sure they're comprehensive. They typically
- 26:24Speaker 1: test for all a lot of things. I want to
- 26:26Speaker 1: make sure that it's completed by you know, a third
- 26:29Speaker 1: party lab not the company themselves. Make sure they're a
- 26:32Speaker 1: lots specific in record and repeat, not just once from
- 26:35Speaker 1: five years ago, and that they're readily available typically at
- 26:38Speaker 1: QR code these days, right, so that leads us to
- 26:41Speaker 1: the whole you know, topical cannabinoid or topical CBD specifically
- 26:45Speaker 1: products typically got creams, gels.
- 26:47Speaker 2: A oointments.
- 26:48Speaker 1: You know, just like the rest of the gang. Human
- 26:51Speaker 1: skin absorption rate is pretty low. CBD is said to
- 26:54Speaker 1: be a little bit more than thpc. But yeah, tomato, tomato,
- 26:58Speaker 1: like anything. You know, we kind of got to check
- 27:00Speaker 1: ourselves on this when we say, oh, these topicals have
- 27:02Speaker 1: very low absorption.
- 27:04Speaker 2: Isn't that the point? Sometimes?
- 27:06Speaker 1: You know, you don't want as much systemic absorption, you
- 27:08Speaker 1: don't want it throughout the whole body. To get all
- 27:10Speaker 1: the rest of the baggage, we call them side effects. Right,
- 27:14Speaker 1: that being said, things we've heard of for getting around
- 27:18Speaker 1: the low absorption. You know, certainly higher concentrations could potentially
- 27:22Speaker 1: help with that.
- 27:23Speaker 2: Playing generously going.
- 27:24Speaker 1: All Baywatch from back in the nineties, I guess, you know,
- 27:27Speaker 1: for applying generously may be able to But you know,
- 27:31Speaker 1: that's the big picture overall. We got to have smart goals.
- 27:35Speaker 1: They got to be measurable and attainable for what we're
- 27:37Speaker 1: looking for from our topical agents. We don't want to
- 27:40Speaker 1: set the bar too high for our patients quite frankly,
- 27:42Speaker 1: whether prescription or over the counter or whatever. You know,
- 27:46Speaker 1: we want to be reasonable in our goals overall, typically
- 27:49Speaker 1: complementary to other pain management treatment options in the overall
- 27:53Speaker 1: toolbox right now, nothing new here, of course.
- 27:56Speaker 2: These topical CBD.
- 27:57Speaker 1: Products have been in pharmacies for years now, and they're
- 28:00Speaker 1: everywhere else as well now too, right, So that's why
- 28:03Speaker 1: I just want to add that on here where it's
- 28:06Speaker 1: not really prescription but kind of sort of something maybe, right,
- 28:10Speaker 1: But you know, to have two episodes talking about topical
- 28:13Speaker 1: pain medicines and not touch on.
- 28:14Speaker 2: CBD products for more than twelve.
- 28:16Speaker 1: Seconds, that would be a loss, right, So wanted to
- 28:19Speaker 1: do that here for us today on the Pain Pod.
- 28:22Speaker 1: All right, we want to keep things as a synct
- 28:24Speaker 1: as possible, So we went over the nuts and bolts
- 28:26Speaker 1: of the primary prescription topical pain medicines, added in a
- 28:31Speaker 1: couple compounds and a couple readily available things as well
- 28:34Speaker 1: overall to make life a little bit easier for clinicians
- 28:37Speaker 1: and patients alike, and then also added in a little
- 28:40Speaker 1: touch of CBD on their topically as well. Right, So
- 28:43Speaker 1: I hope this perhaps intertwined and kind of added on
- 28:49Speaker 1: to the first topical pain medicine episode here on the
- 28:51Speaker 1: Pain Pod. Serve you well, whether clinician, whether patient, whether
- 28:56Speaker 1: lay person, whoever, and everyone right. But I thank you,
- 29:01Speaker 1: of course for your time and for tuning into the
- 29:04Speaker 1: Pain Pod once again, and as always, I wish you
- 29:08Speaker 1: a great day every day.
- 29:11Speaker 3: If you'd like to join Mark on the Pain Pod,
- 29:14Speaker 3: send us an email to publish You're at pharmacypodcast dot com,
- 29:19Speaker 3: and make sure to share the show and subscribe on
- 29:21Speaker 3: your favorite podcast directory. Thanks for listening.